Comprehensive validation services for the Chinese market
Opening of Sartorius Stedim Biotech’s new validation service laboratory in Shanghai: Dr. Jörg Lindenblatt, SSB’s Senior Vice President of Sales for Bioprocess Solutions in Asia (4th from left), joined by business partners and colleagues in cutting the ribbon
Goettingen, Germany | Shanghai, China – January 12, 2017: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, opened a new validation service laboratory yesterday at its site in Shanghai Zhangjiang Hi-Tech Park. The opening event was attended by business partners from the biopharmaceutical industry and representatives of the local community.
With its new laboratory, Sartorius Stedim Biotech is making validation of membrane filters even more convenient and time-saving. Chinese customers can have their entire process steps validated locally and will also benefit from direct interaction with Sartorius specialists on site. “Our Shanghai validation lab provides high-quality services that are fully compliant with applicable GMP and GLP principles. At this validation service lab, we now offer comprehensive process validation studies for the strongly growing Chinese pharma market,” stated Dr. Jörg Lindenblatt, SSB’s Senior Vice President of Sales for Bioprocess Solutions in Asia, in his opening speech. The validation lab, together with SSB’s Application Center in Shanghai, provides a full range of extended services to the biopharmaceutical industry.
SSB’s new Shanghai laboratory covers approximately 4,000 square feet (370 square meters). Equipped with the latest instrumentation, it offers microbiological testing services and physical-chemical testing to provide a full range of data for process validation studies in compliance with all regulatory requirements. Certified according to Biosafety Level II (BSL-2), the facility is permitted to handle specific critical bacteria and customer products.
A Profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a global reach. The company employs approx. 4,200 people, and earned sales revenue of 884.3 million euros in 2015